-
Something wrong with this record ?
Speech biomarkers in Huntington's disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages
T. Kouba, W. Frank, T. Tykalova, A. Mühlbäck, J. Klempíř, KS. Lindenberg, GB. Landwehrmeyer, J. Rusz
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
36732902
DOI
10.1111/ene.15726
Knihovny.cz E-resources
- MeSH
- Biomarkers MeSH
- Huntington Disease * complications genetics psychology MeSH
- Cognition Disorders * complications MeSH
- Humans MeSH
- Cross-Sectional Studies MeSH
- Speech MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND AND PURPOSE: Motor speech alterations are a prominent feature of clinically manifest Huntington's disease (HD). Objective acoustic analysis of speech can quantify speech alterations. It is currently unknown, however, at what stage of HD speech alterations can be reliably detected. We aimed to explore the patterns and extent of speech alterations using objective acoustic analysis in HD and to assess correlations with both rater-assessed phenotypical features and biological determinants of HD. METHODS: Speech samples were acquired from 44 premanifest (29 pre-symptomatic and 15 prodromal) and 25 manifest HD gene expansion carriers, and 25 matched healthy controls. A quantitative automated acoustic analysis of 10 speech dimensions was performed. RESULTS: Automated speech analysis allowed us to differentiate between participants with HD and controls, with areas under the curve of 0.74 for pre-symptomatic, 0.92 for prodromal, and 0.97 for manifest stages. In addition to irregular alternating motion rates and prolonged pauses seen only in manifest HD, both prodromal and manifest HD displayed slowed articulation rate, slowed alternating motion rates, increased loudness variability, and unstable steady-state position of articulators. In participants with premanifest HD, speech alteration severity was associated with cognitive slowing (r = -0.52, p < 0.001) and the extent of bradykinesia (r = 0.43, p = 0.004). Speech alterations correlated with a measure of exposure to mutant gene products (CAG-age-product score; r = 0.60, p < 0.001). CONCLUSION: Speech abnormalities in HD are associated with other motor and cognitive deficits and are measurable already in premanifest stages of HD. Therefore, automated speech analysis might represent a quantitative HD biomarker with potential for assessing disease progression.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011616
- 003
- CZ-PrNML
- 005
- 20230801133209.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/ene.15726 $2 doi
- 035 __
- $a (PubMed)36732902
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kouba, Tomas $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic
- 245 10
- $a Speech biomarkers in Huntington's disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages / $c T. Kouba, W. Frank, T. Tykalova, A. Mühlbäck, J. Klempíř, KS. Lindenberg, GB. Landwehrmeyer, J. Rusz
- 520 9_
- $a BACKGROUND AND PURPOSE: Motor speech alterations are a prominent feature of clinically manifest Huntington's disease (HD). Objective acoustic analysis of speech can quantify speech alterations. It is currently unknown, however, at what stage of HD speech alterations can be reliably detected. We aimed to explore the patterns and extent of speech alterations using objective acoustic analysis in HD and to assess correlations with both rater-assessed phenotypical features and biological determinants of HD. METHODS: Speech samples were acquired from 44 premanifest (29 pre-symptomatic and 15 prodromal) and 25 manifest HD gene expansion carriers, and 25 matched healthy controls. A quantitative automated acoustic analysis of 10 speech dimensions was performed. RESULTS: Automated speech analysis allowed us to differentiate between participants with HD and controls, with areas under the curve of 0.74 for pre-symptomatic, 0.92 for prodromal, and 0.97 for manifest stages. In addition to irregular alternating motion rates and prolonged pauses seen only in manifest HD, both prodromal and manifest HD displayed slowed articulation rate, slowed alternating motion rates, increased loudness variability, and unstable steady-state position of articulators. In participants with premanifest HD, speech alteration severity was associated with cognitive slowing (r = -0.52, p < 0.001) and the extent of bradykinesia (r = 0.43, p = 0.004). Speech alterations correlated with a measure of exposure to mutant gene products (CAG-age-product score; r = 0.60, p < 0.001). CONCLUSION: Speech abnormalities in HD are associated with other motor and cognitive deficits and are measurable already in premanifest stages of HD. Therefore, automated speech analysis might represent a quantitative HD biomarker with potential for assessing disease progression.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Huntingtonova nemoc $x komplikace $x genetika $x psychologie $7 D006816
- 650 _2
- $a řeč $7 D013060
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a kognitivní poruchy $x komplikace $7 D003072
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Frank, Wiebke $u Department of Neurology, University Ulm, Ulm, Germany
- 700 1_
- $a Tykalova, Tereza $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic
- 700 1_
- $a Mühlbäck, Alzbeta $u Department of Neurology, University Ulm, Ulm, Germany $u Department of Neuropsychiatry, Huntington Center South, kbo-Isar-Amper-Klinikum Taufkirchen (Vils), Taufkirchen, Germany $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Klempíř, Jiří $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Lindenberg, Katrin S $u Department of Neurology, University Ulm, Ulm, Germany
- 700 1_
- $a Landwehrmeyer, G Bernhard $u Department of Neurology, University Ulm, Ulm, Germany
- 700 1_
- $a Rusz, Jan $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $u Department of Neurology & ARTORG Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland $1 https://orcid.org/0000000210363054 $7 xx0093732
- 773 0_
- $w MED00001629 $t European journal of neurology $x 1468-1331 $g Roč. 30, č. 5 (2023), s. 1262-1271
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36732902 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801133205 $b ABA008
- 999 __
- $a ok $b bmc $g 1963822 $s 1197881
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 30 $c 5 $d 1262-1271 $e 20230222 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
- LZP __
- $a Pubmed-20230718
